These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

335 related items for PubMed ID: 32657875

  • 41. Gallium-68-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study.
    Naswa N, Sharma P, Kumar A, Nazar AH, Kumar R, Chumber S, Bal C.
    AJR Am J Roentgenol; 2011 Nov; 197(5):1221-8. PubMed ID: 22021518
    [Abstract] [Full Text] [Related]

  • 42. Well-differentiated gastro-entero-pancreatic neuroendocrine tumors with positive FDG-PET/CT: a retrospective chart review.
    Haidar M, Al Mahmasani L, Chehade L, Elias C, El Jebai M, Temraz S, Charafeddine M, Al Darazi M, Shamseddine A.
    Nucl Med Commun; 2023 Jun 01; 44(6):471-479. PubMed ID: 36897058
    [Abstract] [Full Text] [Related]

  • 43. Evaluation of 68Ga-DOTATOC PET/MRI for whole-body staging of neuroendocrine tumours in comparison with 68Ga-DOTATOC PET/CT.
    Sawicki LM, Deuschl C, Beiderwellen K, Ruhlmann V, Poeppel TD, Heusch P, Lahner H, Führer D, Bockisch A, Herrmann K, Forsting M, Antoch G, Umutlu L.
    Eur Radiol; 2017 Oct 01; 27(10):4091-4099. PubMed ID: 28439648
    [Abstract] [Full Text] [Related]

  • 44. [Contemporary nuclear medicine diagnostics of neuroendocrine tumors].
    Srp Arh Celok Lek; 2015 Oct 01; 143(1-2):108-15. PubMed ID: 25845263
    [Abstract] [Full Text] [Related]

  • 45. Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours.
    Kumar R, Sharma P, Garg P, Karunanithi S, Naswa N, Sharma R, Thulkar S, Lata S, Malhotra A.
    Eur Radiol; 2011 Nov 01; 21(11):2408-16. PubMed ID: 21750886
    [Abstract] [Full Text] [Related]

  • 46. 68 Ga-DOTATATE Positron Emission Tomography-Computed Tomography Quantification Predicts Response to Somatostatin Analog Therapy in Gastroenteropancreatic Neuroendocrine Tumors.
    Lee H, Eads JR, Pryma DA.
    Oncologist; 2021 Jan 01; 26(1):21-29. PubMed ID: 32886441
    [Abstract] [Full Text] [Related]

  • 47. Qualitative and quantitative image analysis of CT and MR imaging in patients with neuroendocrine liver metastases in comparison to (68)Ga-DOTATOC PET.
    Flechsig P, Zechmann CM, Schreiweis J, Kratochwil C, Rath D, Schwartz LH, Schlemmer HP, Kauczor HU, Haberkorn U, Giesel FL.
    Eur J Radiol; 2015 Aug 01; 84(8):1593-1600. PubMed ID: 25999064
    [Abstract] [Full Text] [Related]

  • 48. Early Dynamic 68Ga-DOTA-D-Phe1-Tyr3-Octreotide PET/CT in Patients With Hepatic Metastases of Neuroendocrine Tumors.
    Sänger PW, Freesmeyer M.
    Clin Nucl Med; 2016 Jun 01; 41(6):447-53. PubMed ID: 26859210
    [Abstract] [Full Text] [Related]

  • 49. Evaluation of (68)Ga-DOTANOC PET/CT imaging in a large exclusive population of pancreatic neuroendocrine tumors.
    Sharma P, Arora S, Dhull VS, Naswa N, Kumar R, Ammini AC, Bal C.
    Abdom Imaging; 2015 Feb 01; 40(2):299-309. PubMed ID: 25134801
    [Abstract] [Full Text] [Related]

  • 50. (68)Ga-DOTA-peptide: A novel molecular biomarker for nasopharyngeal carcinoma.
    Khor LK, Loi HY, Sinha AK, Tong KT, Goh BC, Loh KS, Lu SJ.
    Head Neck; 2016 Apr 01; 38(4):E76-80. PubMed ID: 26275126
    [Abstract] [Full Text] [Related]

  • 51. Prevalence of metastases outside the liver and abdominal lymph nodes on 68Ga-DOTATOC-PET/CT in patients with small intestinal and pancreatic neuroendocrine tumours.
    Wedin M, Janson ET, Wallin G, Sundin A, Daskalakis K.
    J Neuroendocrinol; 2024 May 01; 36(5):e13391. PubMed ID: 38590270
    [Abstract] [Full Text] [Related]

  • 52. Added value of [68Ga]Ga-DOTA-TOC PET/CT for characterizing pancreatic neuroendocrine neoplasms: a comparison with contrast-enhanced CT and/or MRI in a large study cohort.
    Yoo J, Kim SH, Jeon SK, Bae JS, Han JK.
    Eur Radiol; 2021 Oct 01; 31(10):7734-7745. PubMed ID: 33787974
    [Abstract] [Full Text] [Related]

  • 53. The Accessory Spleen Is an Important Pitfall of 68Ga-DOTANOC PET/CT in the Workup for Pancreatic Neuroendocrine Neoplasm.
    Rufini V, Inzani F, Stefanelli A, Castaldi P, Perotti G, Cinquino A, Indovina L, Rindi G.
    Pancreas; 2017 Feb 01; 46(2):157-163. PubMed ID: 27846139
    [Abstract] [Full Text] [Related]

  • 54. Added value of pretreatment (18)F-FDG PET/CT for staging of advanced gastric cancer: Comparison with contrast-enhanced MDCT.
    Kawanaka Y, Kitajima K, Fukushima K, Mouri M, Doi H, Oshima T, Niwa H, Kaibe N, Sasako M, Tomita T, Miwa H, Hirota S.
    Eur J Radiol; 2016 May 01; 85(5):989-95. PubMed ID: 27130061
    [Abstract] [Full Text] [Related]

  • 55. Gadoxetate-enhanced versus diffusion-weighted MRI for fused Ga-68-DOTANOC PET/MRI in patients with neuroendocrine tumours of the upper abdomen.
    Mayerhoefer ME, Ba-Ssalamah A, Weber M, Mitterhauser M, Eidherr H, Wadsak W, Raderer M, Trattnig S, Herneth A, Karanikas G.
    Eur Radiol; 2013 Jul 01; 23(7):1978-85. PubMed ID: 23471430
    [Abstract] [Full Text] [Related]

  • 56. Gastroenteropancreatic neuroendocrine tumors: impact of consistent contrast agent selection on radiologists' confidence in hepatic lesion assessment on restaging MRIs.
    Balthazar P, Shinagare AB, Tirumani SH, Jagannathan JP, Ramaiya NH, Khorasani R.
    Abdom Radiol (NY); 2018 Jun 01; 43(6):1386-1392. PubMed ID: 28840281
    [Abstract] [Full Text] [Related]

  • 57. Oncogenic osteomalacia: role of Ga-68 DOTANOC PET/CT scan in identifying the culprit lesion and its management.
    Singh D, Chopra A, Ravina M, Kongara S, Bhatia E, Kumar N, Gupta S, Yadav S, Dabadghao P, Yadav R, Dube V, Kumar U, Dixit M, Gambhir S.
    Br J Radiol; 2017 Apr 01; 90(1072):20160811. PubMed ID: 28181822
    [Abstract] [Full Text] [Related]

  • 58. Ga-68 DOTANOC PET/CT imaging in detection of primary site in patients with metastatic neuroendocrine tumours of unknown origin and its impact on clinical decision making: experience from a tertiary care centre in India.
    Pruthi A, Pankaj P, Verma R, Jain A, Belho ES, Mahajan H.
    J Gastrointest Oncol; 2016 Jun 01; 7(3):449-61. PubMed ID: 27284479
    [Abstract] [Full Text] [Related]

  • 59. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
    Panagiotidis E, Alshammari A, Michopoulou S, Skoura E, Naik K, Maragkoudakis E, Mohmaduvesh M, Al-Harbi M, Belda M, Caplin ME, Toumpanakis C, Bomanji J.
    J Nucl Med; 2017 Jan 01; 58(1):91-96. PubMed ID: 27516446
    [Abstract] [Full Text] [Related]

  • 60. The significance of incidental brain uptake on 68Ga-DOTATATE PET-CT in neuroendocrine tumour patients.
    Cleary JO, Yeung J, McMeekin H, Wilhelm T, Wagner T.
    Nucl Med Commun; 2016 Nov 01; 37(11):1197-205. PubMed ID: 27399848
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.